Market cap
$3 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.7
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -- | -- | -- | -- | -- |
| EBIT | -- | -- | -25.49 | -8.47 | -193.30 |
| Net Profit | 17.95 | 24.65 | -20.64 | -10.26 | -194.83 |
| EPS | 77.64 | -330.64 | -1,476.22 | -306.78 | -227.33 |
| Book Value | -- | -- | -- | -- | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-25 | Dec-24 |
| EBIT-Margin
| -- | -- | -- | -- | -- |
| Net Margin
| -- | -- | -- | -- | -- |
| Return on equity
| -- | -- | -- | -1,625.11 | -134.52 |
| Return on Capital
| -- | -- | -- | -1,088.21 | -133.36 |
| Return on Assets
| -- | -- | -140.92 | -343.49 | -110.77 |
| Debt to Equity (x)
| -- | -- | 0.00 | -0.53 | 0.04 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Aug-23
|
|---|---|---|---|---|---|
|
Artelo Biosciences (ARTL)
|
--
|
-1,088.21
|
-133.36
|
-59.47
|
-50.81
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
--
--
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Aug-23
|
|---|---|---|---|---|---|
|
Artelo Biosciences (ARTL)
|
--
|
-1,625.11
|
-134.52
|
-59.63
|
-50.89
|
|
Peer Median
|
-40.33
|
--
|
--
|
--
|
--
|
ROA
-140.92
Lower than Peers by 109.68
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Aug-23
|
|---|---|---|---|---|---|
|
Artelo Biosciences (ARTL)
|
-140.92
|
-343.49
|
-110.77
|
-55.51
|
-48.35
|
|
Peer Median
|
-31.24
|
--
|
--
|
--
|
--
|
EBIT Growth
--
--
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Aug-23
|
|---|---|---|---|---|---|
|
Artelo Biosciences (ARTL)
|
--
|
-25.49
|
-1.79
|
3.47
|
--
|
|
Peer Median
|
-1.02
|
--
|
--
|
--
|
--
|
Net Profit Growth
-20.64
Lower than Peers by 13.11
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Aug-23
|
|---|---|---|---|---|---|
|
Artelo Biosciences (ARTL)
|
-20.64
|
-31.07
|
-5.78
|
7.87
|
2.07
|
|
Peer Median
|
-7.53
|
--
|
--
|
--
|
--
|
EPS Growth
-1,476.22
Lower than Peers by 1,490.45
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Aug-23
|
|---|---|---|---|---|---|
|
Artelo Biosciences (ARTL)
|
-1,476.22
|
-7.11
|
-0.04
|
0.18
|
--
|
|
Peer Median
|
14.23
|
--
|
--
|
--
|
--
|
Book Value Growth
2,131.23
Higher than Peers by 2,141.36
Year on year growth in book value per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Aug-23
|
|---|---|---|---|---|---|
|
Artelo Biosciences (ARTL)
|
2,131.23
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-10.13
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Aug-23
|
|---|---|---|---|---|---|
|
Artelo Biosciences (ARTL)
|
--
|
-0.53
|
0.04
|
0.00
|
0.00
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
0.01
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Aug-23
|
|---|---|---|---|---|---|
|
Artelo Biosciences (ARTL)
|
0.01
|
-0.51
|
0.01
|
0.00
|
0.00
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
3.00
Lower than Peers by 2.81
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Aug-23
|
|---|---|---|---|---|---|
|
Artelo Biosciences (ARTL)
|
3.00
|
0.17
|
1.44
|
8.51
|
18.36
|
|
Peer Median
|
5.81
|
--
|
--
|
--
|
--
|
Quick Ratio
3.00
Lower than Peers by 2.69
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Aug-23
|
|---|---|---|---|---|---|
|
Artelo Biosciences (ARTL)
|
3.00
|
--
|
--
|
--
|
--
|
|
Peer Median
|
5.70
|
--
|
--
|
--
|
--
|
Interest Coverage
-19.50
Lower than Peers by 17.42
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Aug-23
|
|---|---|---|---|---|---|
|
Artelo Biosciences (ARTL)
|
-19.50
|
-65.39
|
--
|
--
|
-2,057.40
|
|
Peer Median
|
-2.09
|
--
|
--
|
--
|
--
|
Operating Efficiency
Asset Turnover
--
--
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Aug-23
|
|---|---|---|---|---|---|
|
Artelo Biosciences (ARTL)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.06
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
--
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Aug-23
|
|---|---|---|---|---|---|
|
Artelo Biosciences (ARTL)
|
--
|
-0.02
|
-0.17
|
-0.24
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Price / Book Value
0.69
Lower than Peers by 4.64
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Aug-23
|
|---|---|---|---|---|---|
|
Artelo Biosciences (ARTL)
|
0.69
|
-0.25
|
0.60
|
0.19
|
--
|
|
Peer Median
|
5.33
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Aug-23
|
|---|---|---|---|---|---|
|
Artelo Biosciences (ARTL)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
1.22
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Aug-23
|
|---|---|---|---|---|---|
|
Artelo Biosciences (ARTL)
|
1.22
|
-0.03
|
0.05
|
0.88
|
1.70
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
3
Lower than Peers by 138
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Aug-23
|
|---|---|---|---|---|---|
|
Artelo Biosciences (ARTL)
|
3
|
--
|
--
|
--
|
--
|
|
Peer Median
|
142
|
--
|
--
|
--
|
--
|